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Abstract. 
New diclofenac derivatives containing L-phenylanline moiety were synthesized, and fully characterized using 
different tools such IR, 
1
H NMR, 
13
C NMR spectroscopy.  In order to gain the inhibition actions of  the 
synthesized compounds against cyclooxygenases, its compounds were docked  into the active sites of (COX-1 
and COX-2) compared with reference drug. The Docking studies were predicted that, the lowest energies and 
high binding scores of docked compounds, which interacted with active site, perhaps making them possible 
physiologically  active as  selective inhibitors against (COX-2), and may considered them a suitable selective 
inhibitor against   (COX-2). 
Keywords:  Phenylalanine, Diclofenac, COX, DOCKING, ADMET. 
1. Introduction.  
Non-steroidal anti-inflammatory drugs (NSAIDs) widely employed in musculoskeletal diseases, and 
anti-inflammatory properties [1].  The NSAIDs are effective in different clinical setting, and act as COX 
inhibitors (COX-1 and COX-2) through inhibiting the production of prostaglandins (PGs) [2-4]. Diclofenac is  
one of most famous available members of this drug’s class under current clinical usage [5], and suffer from a 
common toxicity of gastrointestinal drawback, due to inhibition non-selectively of cyclooxygenases enzymes [6–
8]. In addition, diclofenac have anti-microbial [9-11], ulcerogenic, analgesic, anti-inflammatory, lipid 
peroxidation [12,13],  antitumor [14] and inhibitor  formation of transthyretin amyloid fibril properties [15]. 
Fruthermore, the alaninyl derivatives especially containing amide and thioamide moieties possess diverse 
biological activities, as anti-inflammatory, anti-tumor and antimicrobial activities [16-18].  Hence, the  present  
study  aims  to  synthesis a novel series of diclofenac derivatives containing phenylalanine moiety acting as new 
NASIDs. The molecular docking was carried out, to predict the correct binding  geometries for each ligands at 
the active sites, followed by molecular modeling to identify  the  structural  features  of  these  new  series, which 
may support its postulation, the active compounds  with high binding scores may act as COX inhibitors.  
2. Results and discussion. 
2.1. Chemistry. 
  The synthetic routes to obtain the target compounds 1-16 were depicted in Schemes 1-4. The starting compound 
of 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetyl chloride 3 was carried out according to steps depicted in 
(Scheme 1).  
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(2-(2-((2,6-dichlorophenyl)amino)phenyl)acetyl)-L-phenylalanine 4 was synthesized with two 
strategies, first by coupling of 3 with L-Phenylalanine in THF/TEA/H2O media, another strategy through fused 
diclofenac 2 with amino acid to afford compound 4. The  IR  spectrum of  compound  4  indicated  that, the  
presence  of  a OH and NH function as a broad band (3266 cm
-1
),  and  it’s  the 1HNMR  spectrum showed a 
singlet at (δH 12.68 ppm) due to OH protons of carboxylic. The compound 4, which obtained from two methods 
of preparation, was examined via transmission electron microscope (TEM), and showed that, the average particle 
size obtained from fusion method with range of 10-15 nm diameters, but the particle produced from acid 
chloride method in the range 1 µm diameters (Fig.1). The simplicity preparation of L-free amino acid derivatives 
4 and its high activity,  may be suggest potential application of this synthetic model as anti COX agent. 
 
Fig. 1. TEM images of  the 4 prepared with fission method(upper left),  TEM images of  the 4 prepared with acid chloride 
method (upper right), and representative  ball and stick rendering for the most stable steroisomer form of compound 4 as 
calculated by PM3 semi-empirical molecular orbital calculations (lower). 
 
Compounds 5-7 were synthesized according to the methods were described in (Scheme 2). The free 
amino acid 4 was esterified to the corresponding L-phenylalanine methyl ester derivative 5, characteristic 
1
HNMR displayed peak at (δH 3.75 ppm) for (OMe) protons and disappeared of OH proton for carboxyl peak of 
free acid 4. The L-phenylalanine hydrazide derivative 6 was carried out by refluxing compounds 5 with 
hydrazine hydrate in absolute ethanol, The IR spectrum was exhibited presence of NH2 function at (3340 and 
3139 cm
 -1
). 
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The synthetic pathway for preparing compounds 8-12 were outlined in Scheme 3. The acid chloride 3 
was reacted with  aqueous sodium  azide to furnish the 2-(2-(2,6-dichlorophenylamino)phenyl)acetyl azide 8, 
and converted to ((2-((2,6-dichlorophenyl)amino) benzyl)carbamoyl)-L-phenylalanine 10 via formation 
isocyanate 9, the compound 8 was reacted with L-phenylalanine methyl ester to give compound 6. The methyl 
((2-((2,6-dichlorophenyl)amino)benzyl)carbamoyl)-L-phenylalaninate 11 was prepared by methylation of free 
amino acid derivative 10, and\or  by refluxing isocyanate 9 with L- phenylalanine methyl ester. The ((2-((2,6-
dichlorophenyl)amino)benzyl)carbamoyl)-L-phenylalanine hydrazide 12 was  synthesized  by applying  the  
hydrazinolysis  of  methyl ester 11 with  hydrazine  hydrate  in ethanol.   
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The acid chloride 3, was treated with ammonium thiocyanate in acetone to afford 2-(2-(2,6-
dichlorophenylamino)phenyl)acetyl isothiocyanate 13, which was not isolated from the mixture, and was 
converted into the corresponding ((2-(2-((2,6-dichlorophenyl)amino)phenyl)acetyl)carbamothioyl)-L-
phenylalanine 14 by action of L-phenylalanine, and further modification with SOCl2 in absolute methanol was 
achieved  methyl ((2-(2-((2,6-dichlorophenyl)amino)phenyl)acetyl)carbamothioyl)-L-phenylalaninate 15, which 
underwent hydrazonlysis to gave ((2-(2-((2,6-dichlorophenyl)amino)phenyl)acetyl)carbamothioyl)-L-
phenylalanine hydrazide  16, Scheme 4. 
 
In order to establish enantiomeric purity of isolated compounds, the  specific  rotation  values  were  
determined,  which  was remained  unchanged  after  repeated  crystallization  for  several  times. Furthermore, 
the enantiomeric  excess  (ee)  and distereoisomeric excess (de) values  were determined for synthesized 
compounds, these values based on the stereo configuration of amino acid for  amide  part of the products 4, 10 
and 14, which were obtained through  nucleophilic  addition  of  free  amino  acids on diclofenac.  The  TLC  
analysis was showed,  the  optical purity  of  the  resulting  compounds  were  greater  than 94 %. Thus, as 
expected, the stereo chemical configuration at α-carbon atom of the acid was practically unaffected, and this 
synthetic transformation from chiral α-amino acid could be applied at wide range without any significant loss of 
optical activity.      
2.2. Molecular Modeling. 
2.2.1. Docking studies: 
In brief, two isoforms of COX protein are known: COX-1, is responsible for the physiological 
production of prostaglandins, which is expressed in most tissues, and COX-2, is responsible for the increasing 
production of prostaglandins during inflammation process, which is induced by endotoxins, cytokines and 
mitogens in inflammatory cells [19]. The recently analysis X-ray for the arachidonic acid with COX-2  co-crystal 
was showed, the carboxylate group was coordinated with Tyr-385and Ser-530[20], as well as the action of 
NSAIDs, through the interaction of carboxylate group with Tyr-385 and Ser-530, which was stabilized the 
negative charge of the tetrahedral intermediate [21], and demonstrated that, Tyr-385 and Ser-530 have a 
structural and functional evidence for the importance of them in the chelating of the ligands[22]. In order to 
obtained biological data on a structural basis, through rationalized ligand–protein interaction behavior, the 
molecular docking into the active site of COX was performed for the synthesized compounds using flexible 
method.  All calculations for docking experiment were preformed with MVD 2008.4.00 using MOE 2008.10 
[23,24]. The tested compounds were evaluated in silico (docking), using X-ray crystal structures of COX-1 (ID: 
3N8Y; [25]) and COX-2 (ID: 1PXX; [20]) complexes with diclofenac.  The tested compounds were docked into 
active sites of both enzymes COX-1 and COX-2. The active site of the enzyme was defined, to include residues 
within a 10.0 Å radius to any of the inhibitor atoms. The scoring functions were applied for the most stable 
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docking model to evaluate the binding affinities of the inhibitors, which complexes with (COX) active sites, 
table (1). The complexes were energy-minimized with an MMFF94 force field [26] until the gradient 
convergence 0.05 kcal/mol was reached.  All isolated compounds were docked successfully into the COX active 
sites. Compared with reference inhibitor (diclofenac, 1), the compounds 8 in COX-1 active site exhibited, higher 
binding scores of MOE and MVD (-121.78 and -113.28) Kcal/mol, respectively, (table 1, Fig.2). In addition, in 
COX-2 active site, the compounds 7, 12 and 16 were showed higher score than 1, with MOE (136.94, -133.52 
and 133.72) Kcal/mol and with MVD (-121.3, -102.16 and -106.27) Kcal/mol, respectively, table (1). 
Table1: Docking energy scores (kcal/mol) derived from the MVD with MOE for isolated ligands: 
Cpd. dG.  Int. RMS Eele Evdw Esol MVD R. S. Affinity T.Int. H.B. LE1 LE2 
  
  
  
 COX-1       
Dic. -139.011 -78.583 1.576 2.275 -13.904 35.099 -105.918 -91.750 -41.401 -122.173 -2.492 -5.574 -4.828 
4 -114.135 -70.099 1.357 5.276 -27.554 66.766 -73.2495 23.959 -13.946 -117.008 0 -2.441 0.798 
6 -112.043 -75.852 1.668 0.812 -10.995 78.100 -64.598 129.773 -28.68 -97.552 -2.5 -2.083 4.186 
7 -114.592 -77.949 1.099 30.48 -30.861 91.156 -89.348 42.462 -63.672 -128.488 -4.572 -2.882 1.369 
8 -121.786 -47.346 1.409 -8.244 -43.300 118.335 -113.287 -100.01 -46.292 -136.203 22.916 -8.371 -5.394 
10 -99.0466 -60.663 1.205 -25.855 -29.156 71.478 -22.656 222.54 -11.59 -78.191 -2.522 -0.666 6.545 
11 -104.531 -43.461 1.895 -27.506 -37.526 125.942 -66.321 19.929 -21.55 -94.848 -1.922 -2.009 0.603 
12 -105.772 -97.347 1.282 -4.533 -14.564 43.496 -94.219 86.838 -21.112 -123.217 -5.243 -2.771 2.554 
14 -119.389 -80.023 1.503 -25.553 -16.973 116.436 -58.656 149.513 -47.575 -90.187 -3.687 -1.777 4.530 
15 -119.05 -68.443 1.506 -21.150 -11.836 137.242 -70.273 86.945 -43.246 -107.896 -2.972 -2.066 2.557 
16 -119.09 -50.250 1.502 6.645 -31.879 83.546 -96.309 -88.405 -19.728 -119.566 23.25 -1.314 -5.068 
       COX-2       
Dic. -87.5031 -60.580 1.554 4.56041 10689972 -12.516 -101.573 -1.838 -283.696 -145.109 -2.566 -3.211 -0.061 
4 -118.077 -66.542 1.517 -2.03841 44424352 -18.150 -96.334 -87.851 -178.64 -118.524 -2.004 -5.345 -4.623 
6 -115.515 -64.344 2.537 2.115024 53101028 -10.866 -70.607 113.98 -234.192 -140.187 -5.201 -2.076 3.352 
7 -136.944 -86.591 1.760 -13.2268 64397116 -24.663 -121.317 -57.914 -40.2472 -144.777 -2.928 -3.913 -1.868 
8 -109.616 -89.674 1.984 12.01661 64380680 -23.621 -98.946 0.605 -485.464 -145.237 -1.319 -2.910 0.017 
10 -121.527 -38.7518 2.058 -22.4244 62614892 -11.642 -70.607 113.985 -229.488 -140.187 -5.201 -2.076 3.352 
11 -132.68 -77.125 1.531 15.59195 60838292 -16.238 -93.15 60.298 -206.752 -143.456 -3.968 -2.739 1.773 
12 -133.526 -113.74 1.908 -2.14498 51254160 -13.401 -102.16 25.160 -158.984 -159.507 -2.916 -3.095 0.7624 
14 -132.401 -90.987 1.926 -9.29045 50268552 -13.521 -56.096 215.95 -214.2 -98.859 -5.774 -1.699 6.543 
15 -121.684 -90.290 1.545 -11.5066 67707312 -20.524 -70.788 93.822 -45.416 -93.532 -0.313 -2.082 2.759 
16 -133.727 -68.018 1.380 -26.026 70429696 -43.338 -106.271 -103.02 -25.48 -140.273 -10 42.06 -4.905 
d.G.: free binding energy of the ligand from a given conformer, Int.: binding energy of hydrogen bond  interaction with 
receptor, Eele: the electrostatic interaction with the receptor, Evdw: van der Waals  energies between the ligand and the 
receptor, Esol.: Solvation energy., MVD: Energy score used during docking., R.S.:The re-ranking score. T.Int.:The total 
interaction energy between the pose and the target molecule. H.B.: Hydrogen bonding energy between protein and ligand. 
LE1:MolDock Score divided by Heavy Atoms count. LE2:Rerank Score divided by Heavy Atoms count. 
 
2.2.2. Structures activity relationships: 
 
Fig. 2. The compounds were Docked into the active site; a:  diclofenac into COX-1 using MOE tool. b:  
diclofenac into COX-2. using MOE tool; c: highest docking score compound 8  into COX-1 , H- bonds are in 
blue and pink, (left panel) using MVD and (right panel) using MOE . 
In order to get  a  deeper  insight  into  the  nature  and  type  of  interactions of docked compounds,  the  
complexes  between  each compound and COX receptor were visualized, and depicted in (Figs. 2 and 3).  Since, 
the H bond interactions playing an important role in the structure and function of biological molecules, the 
current ligand-receptor interactions were analyzed on the basis of  H bonding. In order to reduce the complexity, 
hydrophobic and π-cation interactions (>6Å) are not shown in (Figs. 2 and 3).  
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The highest binding score member is 8, which complexes with COX-1, exhibited important interactions 
with Tyr-385 and Ser-530 through azido group; four hydrogen bonds in MVD, and two hydrogen bonds in MOE. 
The compound 8 was stabilized in this binding pocket by adjusting its dichlorophenyl and phenyl rings with 
phenyl ring of Tyr-385 by perpendicular and parallel, respectively. The compound 8 was stabilized with itself by 
arranged two phenyl rings in coplanar position, (Fig.2). 
 
Fig. 3. The Compounds 7, 12 and 16 were docked  into the active site of COX-2. H- bonds are in blue and pink. 
In COX-2 binding site (Fig. 3); i- Compound 7 was arranged in binding pocket by adjusting 
dichlorophenyl ring perpendicular with phenyl ring of Tyr-385, the highest score may be due to formation  
hydrogen bonding interaction between two important residues Tyr-385 and Ser-530; ii- Compound 12, was 
interacted with different modes in two programs, which was interacted by formation of one hydrogen bond with 
Tyr-385 in MVD tool, its compound 12 was stabilized in MOE by formation H-bond with Ser-530 and 
electrostatic bond with Arg-120;  iii- Compound 16 formed H-bond interaction with different manners,  by 
formation of H-bond with Ser-530 in MVD tool, and  H-bond with Tyr-385 with MOE,  and was stabilized in 
binding pocket by arrangement of  dicloro- phenyl ring parallel with Tyr-385 residue.  
The results obtained  clearly revealed  that,  the  amino  acid  residues  close  to  the  reference  
molecules diclofenac (1) are mostly the same as observed in the currently compounds under investigation, which 
complexes with proteins (Figs. 2 and 3). Compared with the original inhibitor 1, the higher binding energies and 
binding process interaction were observed in case of compounds 7, 12 and 16 in COX-2, and the lower binding 
energies of tested compounds in COX-1, these results indicated that, the compounds 7, 12 and 16 act as selective 
inhibitors against COX-2, this could probably due to the presence of hydrazido phenylanline Fragment in the 
synthesized compounds.  
2.2.2. Conformational analysis. 
It is obvious that, possibility existence of the synthesized amino acid derivatives 4-7, 10-12 and 14-16 
in L- and D- optical isomer forms. In trying to achieve better insight into the molecular structure of  the most 
preferentially stereoisomer forms for its compounds, the conformational analysis of the target compounds has 
been performed using the MMFF94 force-field [26]  (calculations  in  vacuo,  bond  dipole option for 
electrostatics, PolakeRibiere algorithm, RMS gradient of 0.01 kcal/ mol) implemented in MOE [23]. The most 
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stable conformer for 4-7, 10-12 and 14-16 were fully geometrical optimized with molecular orbital function PM3 
semi-empirical Hamiltonian molecular orbital calculation MOPAC 7 package [27].  The computed molecular 
parameters, total energy, electronic energy, heat of formation, the highest occupied molecular orbital (HOMO) 
energies, the lowest unoccupied molecular orbital (LUMO) energies and the dipole moment for studied 
compounds were calculated , (table 2).  
 
Fig. 4.  The Lowest energy conformers of  the most active compounds 7,8,12 and 16 as representative examples 
in rendering ball and  stick. 
 
The calculated molecular parameters (table 2) showed, the most stable stereoisomer is the (L) form, this 
may be explained by slightly reduces its calculated energy, and this leads to predominance (L) form structures 
over (D) forms. The lowest minimization energy for the isolated structures 4-7, 10-12 and 14-16 was exhibited 
common arrangement of three phenyl rings in coplanar position, as shown in represented example of most active 
compounds 7, 8, 12 and 16  against (COX) enzymes (Fig. 4),  the higher HOMO energy  values show  the  
molecule  is  a  good  electron  donor, on other hand, the lower HOMO energy values indicate that, a weaker 
ability of the molecules  for donating electron. LUMO energy presents the ability of a molecule for receiving 
electron [28]. 
2.2.3. ADMET factors profiling.  
Oral bioavailability was considered playing an important role for the development of bioactive molecules as 
therapeutic agents. Many potential therapeutic agents fail to reach the clinic because their ADMET (absorption, 
distribution, metabolism, elimination and toxic) Factors. Therefore, a computational study for prediction of 
ADMET properties of the molecules was performed for tested compounds 1-16, by determination of topological 
polar surface area (TPSA), a calculated  percent  absorption  (%ABS) which was estimated  by Zhao et al. 
equation[29], and ‘‘rule of five’’ formulated by Lipinski[30] and established that, the chemical compound could 
be an orally active drug in humans, if no more than one violation of the following rule: i) ClogP (partition 
coefficient between  water  and  octanol < 5, ii)  number  of hydrogen bond donors sites  ≤ 5, iii) number of 
hydrogen bond acceptors sites ≤ 10, iv),  molecular  weight  <500 and  molar refractivity should be between 40-
130.   In addition, the total polar surface area (TPSA) is another key property linked to drug bioavailability, the 
passively absorbed molecules with (TPSA>140) have low oral bioavailability [31].
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Table  2:   The Optimized Calculations Energies at  PM3 molecular orbital for 1-16.  
 
L 
 
D 
Cpd E Eele HF IP HOMO LUMO µ E Eele HF IP HOMO LUMO µ 
1 -67008 -420062 -68.750 6.839 -6.839 -0.108 9.911 -67008 -420062 -68.750 6.839 -6.839 -0.108 9.911 
2 -74052.4 -475725 -52.761 8.634 -8.634 -0.266 0.753 -74052.4 -475725 -52.761 8.634 -8.634 -0.266 0.753 
3 -74215.8 -470924 -4.8395 8.783 -8.783 -0.410 2.500 -74215.8 -470924 -4.8395 8.783 -8.783 -0.410 2.500 
4 -112351 -930612 -66.277 8.815 -8.815 -0.399 2.508 -112341 -917698 -66.443 8.711 -8.711 -0.265 1.732 
5 -112512 -923769 -15.808 8.659 -8.659 -0.338 2.893 -112508 -915558 -16.846 8.710 -8.710 -0.279 2.985 
6 -115785 -989671 -57.266 8.627 -8.627 -0.305 1.787 -115780 -975750 -58.395 8.667 -8.667 -0.236 1.503 
7 -113744 -997388 11.8597 8.693 -8.693 -0.358 3.183 -113734 -984784 10.1223 8.666 -8.666 -0.243 2.360 
8 -78084.5 -526686 71.8880 8.681 -8.681 -0.336 1.454 -78084.5 -526686 71.8880 8.681 -8.681 -0.336 1.454 
9 -80142.6 -526778 -13.710 8.635 -8.635 -0.319 1.355 -80142.6 -526778 -13.710 8.635 -8.635 -0.319 1.355 
10 -129386 -1117041 -88.388 8.499 -8.499 -0.244 3.413 -129349 -1112926 -92.690 8.815 -8.815 -0.335 3.316 
11 -125953 -1045955 -98.99 8.599 -8.599 -0.272 3.057 -125932 -1054926 -100.44 8.809 -8.809 -0.335 3.335 
12 -127346 -1117378 -19.687 8.584 -8.584 -0.325 5.074 -127324 -1109640 5.3761 8.816 -8.816 -0.391 3.912 
13 -77650.2 -520068 43.686 8.799 -8.799 -0.936 2.967 -77650.2 -520068 43.686 8.799 -8.799 -0.936 2.967 
14 -123454 -1065171 -10.104 8.989 -8.989 -1.042 2.024 -123432 -1056425 8.5913 1.271 -8.591 -0.9765 4.381 
15 -126890 -1124079 -27.749 8.970 -8.970 -1.002 1.831 -126885 -1116060 8.9239 -23.965 -8.923 -0.958 2.080 
16 -124850 -1140585 8.9780 39.24 -8.978 -0.928 4.176 -124838 -1123632 8.7754 52.897 -8.775 -0.974 3.253 
E: Total energy (kcal/mol)., E-ele:Electronic energy (kcal/mol),HF: Heat of formation (kcal/mol), IP: Ionization potential 
energy(kcal/mol), HOMO: Highest Occupied Molecular Orbital(eV), LUMO: Lowest Occupied Molecular Orbital(eV), µ: 
Dipole moment(Deby).   
 
All calculated descriptors were performed using MOE Package [23], and their results were disclosed in 
(table 3). Our results revealed that,  the  CLogP (factor of the lipophilicity [32] was less than 5.0,  excluding 3 
and 5, hydrogen bond acceptors between (2-6), hydrogen bond donors between (1-4) and molar refractivity 
values in rang (~73-139), these data show these compounds fulfill Lipinski’s rule.  Also, the absorption percent 
between (~ 60-99%).  
The HOMO and LUMO of a molecule play important roles in intermolecular interactions[33], through 
the  interaction  between  the  HOMO  of  the  drug  with  the LUMO of the receptor and vice versa. The 
interactions were stabilized inversely with energy gap between the interacting orbital's.  Increasing HOMO 
energy and decreasing LUMO energy in the drug molecule lead to enhanced stabilizing interactions, and hence, 
binding with the receptor. Furthermore, the global and local chemical reactivity descriptors for molecules have 
been defined (table 3), like softness (measures stability of molecules and chemical reactivity [34], hardness 
(reciprocal of softness), chemical potential, electronegativity (strength atom for attracting electrons  to itself), 
electrophilicity index (measuring  lowering energy  due  to  maximal  flowing electron between donor and 
acceptor) [34-39]. From (tables 2 and 3), and from compared with reference drug 1, these results were 
concluded, the higher potency compounds 7, 8, 12 and 16 have, higher energy gap, higher  hardness,  lower 
softness, lower electronegativity, higher chemical potential and higher electrophilicty, lower dipolemoment, and 
this may explain the less toxicity  and high  affinity of  its compounds against COX.   
2.3. Pharmacology 
2.3.1. Determination of acute toxicity (LD50) 
The LD50 for diclofenac sodium and isolated compounds were screened, all rats were alive over period 
24 h of observation during treated with dose up to 500 mg\ kg for different compounds, and did not show a 
visible signs of acute toxicity.  LD50  (750 mg\kg) of compounds 4, 7, 10, 12, 15 and 16, LD50 of compounds 6, 
8, 11 and 14 was 550 mg\kg, and for diclofenac sodium was 530 mg\kg. The tested compounds are considered 
non-toxic. Therapeutic index was calculated as ( LD50 \ ED50), the compounds 4,7,10,12 and 15 with value 37.5,  
compounds 6,8,11 and 14 were displayed value 27.5, and 26.5 for diclofenac sodium (table 4). So, the isolated 
compounds 4, 6, 7, 8, 10-12 and 14-17  have higher therapeutic index compared with diclofenac sodium, and 
may be appear to be relatively less toxic as  anti-COX agents. 
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Table 3:  Pharmacokinetic parameters important for good oral bioavailability of   compounds 1-16: 
CPD HBD HBA CLogP V Vol. TPSA %ABS Log S mr ∆E η S χ σ ω 
1 1 2 4.202 0 278.75 29.1 98.9605 -4.91458 73.18 6.73142 3.36571 0.297114 -3.47382 3.47382 1.792701 
2 2 3 4.231 0 255.75 49.33 91.98115 -5.6614 75.46 8.36734 4.18367 0.239025 -4.45039 4.45039 2.367057 
3 3 5 5.131 1 264.5 29.1 98.9605 -5.00443 79.32 8.37253 4.186265 0.238876 -4.59725 4.597255 2.524297 
4 2 4 5.355 1 403.75 78.43 81.94165 -5.41676 117.38 8.4156 4.2078 0.237654 -4.60777 4.60777 2.522879 
5 2 5 6.255 1 410.5 58.2 88.921 -5.26708 79.32 8.3218 4.1609 0.240333 -4.49906 4.49906 2.432351 
6 4 6 5.619 0 420.75 67.43 85.73665 -5.177 122.15 8.32181 4.160905 0.240332 -4.46657 4.466575 2.39735 
7 1 5 4.207 1 419.625 96.25 75.79375 -5.58933 135.65 8.33471 4.167355 0.23996 -4.52585 4.525855 2.457598 
8 1 3 2.915 0 273.375 53.82 90.4321 -5.43965 80.63 8.34486 4.17243 0.239668 -4.50865 4.50865 2.435982 
9 4 6 4.031 1 279.125 58.53 88.80715 -6.16118 105.77 8.31628 4.15814 0.240492 -4.47746 4.47746 2.410651 
10 3 6 5.240 2 451 96.53 75.69715 -5.06224 125.62 8.25563 4.127815 0.242259 -4.37186 4.371855 2.315161 
11 1 2 4.976 0 430.875 107.53 71.90215 -4.79691 130.39 8.32732 4.16366 0.240173 -4.43613 4.43613 2.363215 
12 2 3 3.828 0 445.75 125.35 65.75425 -5.23296 131.93 8.25889 4.129445 0.242163 -4.45494 4.454935 2.40304 
13 3 5 4.685 1 289 73.55 83.62525 -5.64529 108.99 7.86316 3.93158 0.254351 -4.8682 4.8682 3.013975 
14 2 4 5.165 1 443.5 122.55 66.72025 -5.1684 133.61 7.94654 3.97327 0.251682 -5.01624 5.01624 3.166493 
15 2 5 5.429 1 463.25 111.55 70.51525 -6.05019 138.38 7.9685 3.98425 0.250988 -4.98641 4.98641 3.120322 
16 4 6 4.017 0 458.5 140.37 60.57235 -6.46792 139.92 8.0495 4.02475 0.248463 -4.95326 4.95326 3.047989 
TPSA: Polar surface area (A2), %ABS: Absorption percentage, Vol: Volume (A3), HBA: Number of hydrogen bond 
acceptor, HBD: Number of hydrogen bond donor,  V: Number of violation from Lipinski’s rule of five., Log P: Calculated 
lipophilicity., Log S: Solubility parameter, mr: Molar Refractivity, ∆E: Energy Gaps(ev), η: Hardness(ev), S: Softness(ev), χ 
: Electronegativity (ev), σ: chemical potential (ev),  ω:Electrophilicity (ev).   
2.3.2. Acute ulcer genesis. 
The compounds were screened for gastric irritation activity. The ulcerogenic effect of indomethacin and 
newly synthesized compounds were studied at 20 mg /kg in rats. All tested compounds exhibited significant 
reduction in ulcerogenic activity compared with the indomethacin (standard drug), which were showed   high   
severity   index   of 4.50 ± 0.316.  This data confirmed that (table 4), these compounds were showed negligible 
ulcerogenic effect, and may be considered as safer drugs for treating inflammation conditions.  
Table 4: Ulcer gastric effect of rats for tested compounds. 
 
 
 
 
 
 
 
 
 
 
*    Dose= 20 mg/kg., ND: Not detected,  Statistically significant at the corresponding time (p < 0.05). 
 
3. Conclusion.  
A series of Diclofenac derivatives containing L-phenylanline moiety 4-16 were synthesized. The comparative 
docking experiments were carried out on compounds 4-8, 10-12 and 12-16, and reference molecules 1. These 
compounds were stabilized in the binding pocket of COX with a similar binding mode of diclofenac, some 
compounds 7, 12 and 16 with high binding score were showed suitable selective inhibitors against COX-2. The 
compounds under investigation were subjected to ADMET profile theoretically reveled that, these compounds 
were considered well passive oral absorption. The ulcerogenic studies were screened for isolated compounds 4-
8, 10-12 and 14-16, and showed negligible ulcerogenic effect with higher safety and better therapeutic index 
than diclofenac. The molecular docking studies were supported with ulcerogenic effect and through 
understanding the various interactions of ligands and active sites of enzymes, help design novel potent selective 
COX-2 inhibitors. 
Ulcerogenic index Therapeutic 
 index 
LD50       Compounds 
Ulcer Number Ulcer severity  
0.0 0.0 ND ND Control 
11.8 ± 0 .985 22.4 ± 1.652 
ND ND 
Indomethacin  
0.0 0.0 26.5 530 Diclofenac  
0.0 0.0 37.5 750 4 
0.0 0.0 27.5 550 6 
0.0 0.0 37.5 750 7 
0.0 0.0 27.5 550 8 
0.0 0.0 37.5 750 10 
0.0 0.0 27.5 550 11 
0.0 0.0 37.5 750 12 
0.0 0.0 27.5 550 14 
0.0 0.0 37.5 750 15 
0.0 0.0 37.5 750 16 
Chemistry and Materials Research                                                                                                                                                    www.iiste.org 
ISSN 2224- 3224 (Print) ISSN 2225- 0956 (Online) 
Vol.3 No.12, 2013 
 
84 
4. EXPERMINTAL: 
4.1. Instrumentation and materials: 
Melting points were taken on a Griffin melting point apparatus and are uncorrected. Thin layer 
chromatography (Rf) for analytical purposes was carried out on silica gel and developed. Benzidine, ninhydrin, 
and hydroxamate tests used for detection reactions. The IR spectra of the compounds were recorded on a Perkin–
Elmer spectrophotometer model 1430 as potassium bromide pellets and frequencies are reported in cm
-1
. The 
 
NMR spectra were observed on a Varian Genini-300 MHz spectrometer and chemical shifts (δ) are in ppm. The 
mass spectra were recorded on a mass spectrometer HP model MS–QPL000EX (Shimadzu) at 70 eV. Elemental 
analyses (C, H, N) were carried out at the Microanalytical Centre of Cairo University, Giza, Egypt. Transmission 
Electron Microscope (TEM) micrographs were measured using JEOL JEM-1010 Transmission Electron 
Microscope, at an accelerating voltage of 60 kV. Suspensions of the samples were put on carbon foil with a 
micro grid. TEM images were observed with minimum electron irradiation to prevent damage to the sample 
structure. 
4.2. Synthesis: 
4.2.1.   2-[(2,6-Dichlorophenyl)amino]phenyl  acetyl  chloride (3) 
Prepared by reported method and directly used in the next step (40, 41). 
4.2.2.     (2-(2-((2,6-dichlorophenyl)amino)phenyl)acetyl)-L-phenylalanine (4): 
4.2.2.1.  Path 1: 
A mixture of L-phenylalanine (0.01 mol) and 2-(2-(2,6-dichlorophenyl-amino)phenyl)acetic acid  (2; 0.01 
mol) was fused at 280°C  in an oil bath for 15 min. The fused mass was dissolved in ethanol and poured onto 
cold water, the solid obtained was recrystallized from ethanol to give compound (4). 
4.2.2.1. Path 2: 
The  L-phenylalnine  (0.01 mol)  was  dissolved  in a mixture   of   water   (25ml),   THF   (15ml) and  
triethylamine  (2 ml)   were   added,   followed   by  portionwise addition of acid  chloride (3;  0.01 mmol)  
during  30  mins,  temperature  of  the  reaction  mixture  was kept at 10°C  during the addition.  Stirring was 
continued for 3 h at 10°C.  THF  was  removed  by concentration  of  the  reaction  mixture  under  reduced  
pressure; water (30 ml) was added and acidified with 1 N HCL to pH =5. The crude products were filtered and 
recrystallized from ethanol.  The product 4 was chromatographically homogeneous by iodine and benzidine 
development. Brown crystal : yields=81%; Rf=0.55 (CHCl3/EtOH=3/1); mp: 150-52  °C;             =+49.1° 
(EtOH)  ; IR (KBr cm-1) ν; 3266 broad band (OH,NH), 3055 (CHarom.), 2954 (CHali.), 1694(CO),1596(CONH) 
cm1; 1H NMR (300 MHz, Chloroform)  δ= 12.68 (s, 1H-OH), 8. 55 (d, H-NH-Dic.), 7.72 – 7.05 (m, 12H- 
aromatic proton), 6.36(d, H-NH-Phe), 3.85(s, 2H, CH2-Dic.), 2.31-2.04 (t, 1H-CH-Phe), 1.27 (d, 2H-CH2-Phe); 
Anal./Calcd.  for  C23H20Cl2N2O3 (442):  C  (62.44%),  H  (4.52%),  N  (6.33%).   Found: C (62.31);  H (4.55); N, 
(6.32). 
4.2.2. General procedures for synthesis L- amino acid methyl ester  derivatives  ( 6, 11 and 15).   
The free amino acid derivatives  (4, 10 and 14; 0.01 mol) in absolute methanol  (50  ml)  was  cooled  to  0-5  
°C,  and  pure  thionylchlorid  (0.015  mmol)  was  added  dropwise during one hour. The reaction mixture was 
stirred for an additional 3 h at room temperature, and kept overnight. The  solvent  was  removed  by vacuum  
distillation,  the  residual  solid  material  was recrystallized  from  ethanol.  The products 6, 11 and 15   were 
chromatographically homogeneous by iodine and benzidine development.   
 
 
4.2.2.1.  methyl (2-(2-((2,6-dichlorophenyl)amino)phenyl)acetyl)-L-phenylalaninate (6). 
Yellowish brown crystal : yields=57%; Rf=0.86 (CHCl3/EtOH=3/1); mp: 131-33°C;     = +52.38° (c=0.1, 
EtOH) ; IR (KBr cm
-1) ν; 3262 (NH), 3036(CHarom.), 2957 (CHali), 1713(CO), 1659  (CONH) cm
1
; 
1
H NMR (300 
MHz, Chloroform)  δ= 8. 55 (d, H-NH-Dic.), 7.72 – 7.05 (m, 12H- aromatic proton), 6.36(d, H-NH- phe), 3.85(s, 
2H, CH2-Dic.), 3.75(s, 3H, OCH3), 2.31-2.29 (t, 1H-CH-Phe), 1.77 (d, 2H-CH2-Phe); Anal./Calcd. for 
C24H22Cl2N2O3 (456):  C  (63.15 %),  H  (4.82%),  N  (6.14%).   Found: C (63.03); H (4.85); N, (6.13). 
 
 
 
 20D
 20D
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4.2.2.2.  methyl ((2-((2,6-dichlorophenyl)amino)benzyl)carbamoyl)-L-phenylalaninate (11). 
Yellowish brown crystal : yields=57%; Rf=0.71 (CHCl3/EtOH=3/1); mp: 144-46 °C;       = +51.84° 
(EtOH) ; IR (KBr cm
-1) ν; 3396,3277 (NH), 3109(CHarom.), 2988 (CHali), 1696(CO), 1607 (CONH) cm
1
; 
1
H 
NMR (300 MHz, Chloroform)  δ= 8. 55 (d, H-NH-Dic.), 7.52 – 6.81 (m, 12H- Ar-H), 6.34 (d, H-NHCONH), 
6.21(d, H-NHPh-phe), 3.80(s, 2H, CH2-Dic.), 3.77(s, 3H, OCH3), 3.35-3.32 (t, 1H-CH-Phe), 1.19 (d, 2H-CH2-Phe); 
Anal./Calcd. for C24H23Cl2N3O3 (471): C(61.14 %),  H  (4.88%),  N  (8.91%).   Found: C (61.01); H (4.63); 
N, (8.40). 
4.2.2.3.  methyl ((2-(2-((2,6-dichlorophenyl)amino)phenyl)acetyl)carbamothioyl)-L-phenylalaninate (15). 
Yellowish brown crystal : yields=60%; Rf=0.73 (CHCl3/EtOH=3/1); mp: 148-150 °C;     = +53.77° (EtOH) ; 
IR (KBr cm
-1) ν; 3362 (NH), 3150(CHarom.), 2950 (CHali), 1693(CO), 1586 (CONH) cm
1
; 
1
H NMR (300 MHz, 
Chloroform)  δ= 8. 55 (d, H-NH Dic.), 7.72 – 7.15 (m, 12H- Ar-H), 7.05 (d, H-NHCSNH), 6.36(d, H-NHPh-phe), 
3.85(s, 2H, CH2-Dic.), 3.71(s, 3H, OCH3), 2.04 (t, 1H-CH-Phe), 1.32 (d, 2H-CH2-Phe); Anal./Calcd. for 
C25H23Cl2N3O3S (515): C(58.25 %),  H  (4.46%),  N  (8.15%).   Found: C (58.14); H (4.49); N, (8.14). 
4.2.3. General procedures for synthesis L- amino acid hydrazide ( 7, 12 and 16).  
L-amino acid methyl ester derivatives   (6, 11 and 15; 0.01 mol) were dissolved  in  a  solution  
containing  ethanol  (100  ml)  and 85 % hydrazine hydrate (6.3 ml), the mixture was refluxed  for  1/2h.,  then  
left  overnight  at  25ºC.  The product was separated, and collected by  suction  filtration,    washed    with    
methanol    and    light  petroleum ether,  and  recrystallized from ethanol  to give desired  hydrazid  compound 
derivatives  (7, 12 and 16). 
4.2.3.1(2-(2-((2,6-dichlorophenyl)amino)phenyl)acetyl)-L-phenylalanine hydrazide (7). 
white crystal; yields=84%; Rf=0.80 (CHCl3/MeOH=3/1); mp: 178-181  °C;      =+52.81°  (EtOH); IR 
(KBr cm
-1) ν; 3340, 3139 (NH2 ,NH), 3014(CH arom.), 2911,2851(CHali), 1687 (CO), 1617,1582 (CONH) cm
-1
;
 1
H 
NMR (300 MHz, Chloroform) δ = 8.01(d, 1H-NH-Dic.) 7.66– 7.12 (m,12H-Ar-H), 6.89(d,1H, NH- phe.), 4.90(s, 
1H-NHNH2), 4.25(s, 2H-NHNH2), 3.84 (s, 2H- CH2-DIC.), 1.90(t, 1H-CH-Phe), 1.14 (d, 2H-CH2-Phe); 
13
CNMR  
(CD3OD); δ= 161.74,160.11 (CONH and CONHNH2), 114.77, 116.26, 118.41, 120.25, 123.95, 127.91, 129.84, 
132.81, 134.079, 145.64, 153.40, 155.20, 157.71 (ArC,  ArCH), 40.33  (CH-Phe), 39.77 (CH2-Phe), 38.66(CH2-
Dic.); Anal./Calcd.  for  C23H22Cl2N4O2 (456):  C  (60.52%),  H  (4.82%),  N  (12.28%). Found: C (60.40);  H 
(4.85); N, (12.25).  
4.2.3.2. ((2-((2,6-dichlorophenyl)amino)benzyl)carbamoyl)-L-phenylalanine hydrazide (12). 
white crystal; yields= 50%; Rf=0.69 (CHCl3/MeOH=3/1); mp:210-12°C;     =+53.01°  (EtOH); IR 
(KBr cm-1) ν; 3331, 3248 (NH2 ,NH), 3018(CH arom.), 2959 (CHali), 1694 (CO), 1582 (CONH) cm-1; 1H 
NMR (300 MHz, Chloroform) δ =8.11(d, 1H-NH-Dic.), 7.66– 7.12 (m,13H,[12H-ArH+1H-NHCONH), 
6.89(s,1H, NH- phe.), 4.90 (s, 1H-NHNH2), 4.55(s, 2H-NHNH2), 3.84 (s, 2H- CH2-DIC.), 3.33 (t, 1H-CH-Phe), 
1.14 (d, 2H-CH2-Phe); 13CNMR  (CD3OD); δ= 163.56, 162.93 (CONHCO and CONHNH2), 
153.93(CONHCO), 115.66, 116.53, 120.11,  120.67, 120.72 (ArC,  ArCH),  40.66  (CH-Phe), 39.22 (CH2-Phe), 
37.08(CH2-Dic.); Anal./Calcd.  for  C23H23Cl2N5O2 (471):  C  (58.59%),  H  (4.88%),  N  (14.86%). Found: C 
(57.61);  H (4.63); N, (14.00).  
  
4.2.3.3. ((2-(2-((2,6-dichlorophenyl)amino)phenyl)acetyl)carbamothioyl)-L-phenylalanine hydrazide (16). 
white crystal; yields=63%;Rf=0.80 (CHCl3/MeOH=3/1); mp:183-85°C ;              =+50.32°  (EtOH); IR 
(KBr cm
-1) ν; 3252, 3248 (NH2 ,NH), 3050(CH arom.), 2992 (CHali), 1710 (CO), 1588 (CONH) cm
-1
;
 1
H NMR 
(300 MHz, Chloroform) δ =8.21(d, 1H-NH-Dic.),  7.66– 7.01 (m,12H-ArH), 6.34(d,1H-NHCSNH), 6.22(d,1H, 
NH- phe.), 5.21 (s, 1H-NHNH2), 4.72(s, 2H-NHNH2), 3.90 (s, 2H- CH2-DIC.), 3.67 (t, 1H-CH-Phe), 2.84 (d, 2H-
CH2-Phe); 
13CNMR  (CD3OD); δ= 185.03(CSNHCO), 160.88 (CONHNH2), 150.72(CONHCS), 120.71, 120.73, 
128.67, 129.81, 129.85, 134.95(ArC, ArCH),  47.96  (CH-Phe), 39.77 (CH2-Phe), 32.35(CH2-Dic.); Anal./Calcd.  
for  C24H23Cl2N5O2S (515):  C  (55.92%),  H  (4.46%),  N  (13.59%). Found: C (55.82);  H (4.49); N, (13.56).  
4.2.4.   2-(2-(2,6-dichlorophenylamino)phenyl)acetyl azide (8). 
The compounds 3 (0.01 mol) in  THF (20 ml),  was added to 35% aqueous sodium azide (2 ml) in 
acetone(15 ml) at 0 °C. The resulting mixture was stirred at 0–5 °C for 5hs. The progress of the reaction was 
monitored by TLC using 40% EtOAc in petroleum ether as a mobile phase. The solvent was evaporated on a 
rotatory evaporator under reduced pressure, and residue obtained was triturated in diethyl, the solid material was 
 20D
 20D
 20D
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filtered under suction and dried to afford the title compound 8 as yellow solid : yields=75%;  Rf=0.57 
(CHCl3/MeOH=3/1); mp 102-104  °C;  IR (KBr cm
-1) ν; 3248 (NH), 3025 (CHarom.), 2978 (CHali), 1694 (CO) 
cm
1
; 
1H NMR (300 MHz, Chloroform) δ = 8.20(s,1H, NH),  7.13 – 8.01 (m,7H-Ar-H),  3.88 (s, 2H- CH2); 
Anal./Calcd.  for  C14H10Cl2N4O (320):  C  (52.50%),  H  (3.12%),  N  (17.50%). Found: C (52.36);  H (3.14); N, 
(17.45).  
4.2.5.  Action of L-Phenylalnine methyl ester on  azide(8). 
 Azide (8; 0.01 mole) in THF (10 ml.) was treated with L-phenylalnine methyl ester (0.015 mole) at 
room temperature. The reaction mixture was refluxed for 10 h. The excess solvent was removed and the solid 
residue was washed with water, and then crystallized  from EtOH  to give  L- amino acid methyl ester 
derivatives (6). 
4.2.6.   2-(2-(2,6-dichlorophenylamino)phenyl)acetyl isocyanate (9). 
The  azide  (8; 0.01mmol) in dry THF (17 ml.) was refluxed at 150–180  °C for a period of 5 h. The 
progress of the reaction mixture was monitored by TLC using 45% EtOH in petroleum ether as a mobile phase.  
The solvent was concentrated, and used immediately in the other reactions without further purification. 
4.2.7. General procedures for synthesis of L- amino acid ureido(10) and thioureido (14) derivatives. 
The isocyanate (9; 0.01mol)  and\ or  isothiocyanate (13; 0.01mol) in THF, the  L-Phenylalanine and 
few drops of pyridine  (0.5 ml.) was added at 0–5 °C, and stirred at same temperature for over a period of 21–26 
h. The solvent was concentrated, and the mixture was treated with cooled ice-water and 0.1N HCl to afford crude 
product. The obtained residue was washed with water, and recrystallized from ethanol to provide the products 10 
and 14.  
4.2.6.1. ((2-((2,6-dichlorophenyl)amino)benzyl)carbamoyl)-L-phenylalanine (10) . 
brown crystal: yields=60%;  Rf=0.60 (petroleum ether /EtOH = 3/1); mp: 205-207°C;     = +51.42° 
(EtOH);  IR (KBr cm
-1) ν; 3210 broad band (OH, NH), 3055 (CHarom.), 2958 (CHali), 1694 (CO), 1602 (CONH) 
cm
1
;  
1H NMR (300 MHz, Chloroform) δ =11.04(s, 1H,OH), 8.44 (d, H-NH-Dic.), 7.72 – 7.05 (m, 12H- Ar-H), 
6.57 (d, H-NHCONH), 6.36(d, H-NHPh-Phe.), 3.85(s, 2H, CH2-Dic.), 2.09 (t, 1H-CH-Phe), 1.87 (d, 2H-CH2-Phe); 
Anal./Calcd. for C23H21Cl2N3O3 (457): C(60.03 %),  H  (4.59%),  N  (9.19%).   Found: C (59.27); H (4.35); N, 
(8.64). 
4.2.6.2. ((2-(2-((2,6-dichlorophenyl)amino)phenyl)acetyl)carbamothioyl)-L-phenylalanine (14). 
browen crystal: yields=78%;  Rf=0.65 (petroleum ether /EtOH=3/1); mp: 196-98  °C;      = +53.82° 
(EtOH) ; IR (KBr cm
-1) ν; 3324, 3128 broad band (OH overlapping NH), 3064 (CHarom.), 2978 (CHali), 
1656(CO), 1586 (CONH) cm
1
;  
1H NMR (300 MHz, Chloroform) δ = 9.93(s, 1H,OH), 8.02 (d, H-NHphe), 7.61 – 
7.36 (m, 12H- aromatic proton), 6.82 (s, H-NHCSNH), 6.58(d, H-NHPh-Dic), 3.85(s, 2H, CH2-Dic.), 1.74 (t, 1H-
CH-Phe), 1.22 (d, 2H-CH2-Phe); Anal./Calcd. for C24H21Cl2N3O3S (501): C(57.48 %),  H  (4.19%),  N  (8.38%).   
Found: C (57.37); H (4.21); N, (8.36). 
4.2.7.  2-(2-(2,6-dichlorophenylamino)phenyl)acetyl isothiocyanate (13). 
The ammonium isothiocyanate (0.01 mol.) in dry acetone (15 ml) was stirred with acid chloride   (3; 
0.01 mmol) in dry THF (10 ml.) at 0–5  °C  over a period of 5 h. The progress of the reaction mixture was 
monitored by TLC using 30% EtOH in petroleum ether as a mobile phase.  The solvent was concentrated, and 
was used immediately in the other reactions without  further  purification. 
4.2.7.1. Action of L-Phenylalnine methyl ester on isocynate (9)  and isothiocyanate (13). 
 The L-Phenylalanine methyl ester (0.01mol) was added to isocyanate (9) isothiocyanate (13) in THF   at 
0–5 °C, and stirred at for a period of 5 hrs. The solvents were evaporated on a rotator evaporator under reduced 
pressure to afford a crude product. The solids were filtered under suction and dried to afford the compounds 11 
and 15. 
4.3. Molecular Modeling Study: 
4.3.1. Generation of Ligand and Enzyme Structures. 
4.3.1.1. Selection of COX structures. 
Docking study was carried out for the target compounds into (COX-1 (ID: 3N8Y) and COX-2 (ID: 1PXX)  
using MVD,4.0  and MOE,10. The crystal structure of the (COX) complexes with (1), which is a selective 
inhibitor of COX-2 in co-crystallized form in the active site of the receptor. From X-ray crystal structure studies 
 20D
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of the COX enzyme, the mouse enzyme is expected to be very similar to the human [19], and can be used as 
model for human COX enzyme. 
4.3.2. Preparation of Small Molecule: 
Molecular modeling of the target compounds were built using MOE, and were minimized their energy with 
PM3 through MOPAC. Our compounds were introduced into the (COX) binding sites according to the published 
crystal structures of (1) bound to kinase.  
     4.3.3. Stepwise Docking Method: 
4.3.3.1. MOE Stepwise 
The crystal structures of the (COX) with a diclofenac (1) as an reference inhibitor molecule was used, 
Water and inhibitor molecule was removed, and hydrogen atoms were added. The parameters and charges were 
assigned with MMFF94x force field.   After alpha-site spheres were generated using the site finder module of 
MOE.  The optimized 3D  structures of molecules  were  subjected  to generate different poses of  ligands  using  
triangular  matcher  placement  method, which generating poses by aligning ligand triplets of atoms on triplets of 
alpha spheres represented in the receptor site points, a random triplet of alpha sphere centers is used to determine 
the pose during each iteration. The pose generated was rescored using London dG scoring function. The poses 
generated were refined with MMFF94x forcefield, also, the solvation effects were treated. The Born solvation 
model (GB/VI) was used to calculate the final energy, and the finally assigned poses were assigned a score based 
on the free energy in kJ/mol 
4.3.3.2. MVD Scorings Stepwise 
Molecular docking was carried out using Molegro Virtual Docker (MVD).  MVD is based on a  differential  
evolution  algorithm;  the  solution  of  the  algorithm  takes  into  account  the  sum  of  the intermolecular  
interaction  energy  between  the  ligand  and  the  protein,  and  the  intramolecular interaction  energy  of  the  
ligand.    The  docking  energy  scoring  function  is  based  on  a  modified piecewise  linear  potential  (PLP)  
with  new  hydrogen  bonding  and  electrostatic  terms  included.   Full description of the algorithm and its 
reliability compared to other common docking algorithm can be found in reference [42, 43]. The small 
molecules and the PDB crystal structure atomic coordinates determined by x-ray crystallography of 1G54 were 
imported, potential binding sites were predicted. The binding cavities were set at X: -6.51, Y: 2.79, Z: 17.44, 
grid resolution was set to 0.3 Å, while the binding site radius was set to 10 Å. The RMSD threshold for multiple 
cluster poses was set at < 1.00Å. The docking algorithm for molecular docking is based on a  differential  
evolution  algorithm;  the  solution  of  the  algorithm  takes  into  account  the  sum  of  the intermolecular  
interaction  energy  between  the  ligand  and  the  protein,  and  the  intramolecular interaction  energy  of  the  
ligand.  
4.4.  Pharmacology. 
4.4.1. Determination of acute toxicity 
 The acute toxicity and lethality (LD50) for the new isolated compounds were estimated in albino mice 
(25–30 g). In a preliminary test, animals in groups of three, received one of 300, 500, 600 or  700  mg\ kg  for 
the tested compounds and diclofenac. Animals were observed for 24 hrs for signs of toxicity and number of 
deaths. The LD50  calculated as the percentage mortality in each group was determined 24 h after 
administration[44].  
4.4.2. Acute ulcer genesis. 
 The studies were carried out on healthy Albino rats at a dose 20 mg\ kg. The animals were divided 
into different groups of six each, group I served as control and received vehicle only, groups II received pure 
indomethacin 20 mg\kg, the other groups were administered test compounds in dose molecularly equivalent to 
20 mg\ kg of indomethacin. Before 24 hrs administration of the tested compounds, Food not water was removed; 
the rats were fed normal diet for 17 hrs and then sacrificed after the drug treatment. The stomach was removed 
and opened along the greater curvature, washed with distilled water and cleaned gently by dipping in saline. The 
mucosal damage was examined by means of a magnifying glass. For each stomach, the mucosal damage was 
assessed according to the following scoring  system[45].   
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